What is SYBX's current stock price?

SYBX (Synlogic, Inc.) is currently trading at $0.60 with a market cap of $7.0M.

What sector is Synlogic, Inc. in?

Synlogic, Inc. (SYBX) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

SYBX Synlogic, Inc.

Healthcare

$0.60+0.67%ClosedMarket Cap: $7.0M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.65

P/S

0.00

EV/EBITDA

1.62

DCF Value

$1.18

FCF Yield

-43.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-5.4%

ROA

-4.4%

ROIC

-36.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$681.0K	$—
Q4 null	$0.00	$1.5M	$—
FY null	$0.00	$-1.0M	$—
Q3 null	$0.00	$-2.3M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Dooley Mary Bethofficer: See Remarks below

SellFri Oct 31

Shea Richard Pdirector

SellTue Apr 29

Flynn James Pdirector

SellTue Apr 29

Dooley Mary Bethofficer: See Remarks below

SellThu Apr 03

Dooley Mary Bethofficer: See Remarks below

SellTue Feb 04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.52

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Peers